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Abstract
Background: Recent studies have demonstrated the association between increased concentrations of high-sensitivity
cardiac troponin T (hs-cTnT) and the incidence of myocardial infarction, heart failure, and mortality. However, most
prognostic studies to date focus on the value of hs-cTnT in the elderly or general population. The value of hs-cTnT in
symptomatic patients visiting the outpatient department remains unclear. The aim of this study was to investigate the
prognostic value of hs-cTnT as a biomarker in patients with symptoms of chest discomfort suspected for coronary artery
disease and to assess its additional value in combination with other risk stratification tools in predicting cardiac events.
Methods: We studied 1,088 patients (follow-up 2.260.8 years) with chest discomfort who underwent coronary calcium
scoring and coronary CT-angiography. Traditional cardiovascular risk factors and concentrations of hs-cTnT, N-terminal pro-
brain-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) were assessed. Study endpoint
was the occurrence of late coronary revascularization (.90 days), acute coronary syndrome, and cardiac mortality.
Results: Hs-cTnT was a significant predictor for the composite endpoint (highest quartile [Q4].6.7 ng/L, HR 3.55; 95%CI
1.88–6.70; P,0.001). Survival analysis showed that hs-cTnT had significant predictive value on top of current risk
stratification tools (Chi-square change P,0.01). In patients with hs-cTnT in Q4 versus ,Q4, a 2- to 3-fold increase in
cardiovascular risk was noticed, either when corrected for high or low Framingham risk score, coronary calcium scoring, or
CT-angiography assessment (HR 3.11; 2.73; 2.47; respectively; all P,0.01). This was not the case for hsCRP and NT-proBNP.
Conclusions: Hs-cTnT is a useful prognostic biomarker in patients with chest discomfort suspected for coronary artery
disease. In addition, hs-cTnT was an independent predictor for cardiac events when corrected for cardiovascular risk
profiling, calcium score and CT-angiography results.
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Introduction
Identification of patients at risk for acute cardiovascular events
remains a challenge. One promising avenue to improve the
identification of these patients is the use of serum biomarkers,
which could provide a relatively easy and cost-effective step in risk
stratification. Several biomarkers have been evaluated with respect
to their incremental diagnostic and prognostic value [1,2].
Elevated concentrations of high-sensitivity C-reactive protein
(hsCRP), an inflammatory biomarker, are associated with future
cardiovascular events, which supports the hypothesis that
atherothrombosis is partly an inflammatory disease [3]. Elevated
concentrations of N-terminal pro-B-type natriuretic peptide (NT-
proBNP), the inactive fragment from BNP which is secreted by the
cardiomyocytes in response to ventricular wall stretch, have also
been associated with an increased risk of death and cardiovascular
events [4]. However, none of these biomarkers have achieved
widespread acceptance in daily practise as a risk stratification tool
for the detection of coronary artery disease (CAD).
With the development of more accurate high-sensitivity cardiac
troponin (hs-cTn) assays, new possibilities become available to
improve risk stratification [5–7]. Recently, we demonstrated the
association between hs-cTnT and CAD, as determined by
coronary computed tomographic angiography (CCTA), in patients
with stable chest pain [8]. We found that even mild CAD is
associated with quantifiable circulating levels of hs-cTnT, which
was confirmed by others [9]. This could be the result of episodes of
cardiac ischemia due to a mismatch between metabolic demand
and supply. An alternative mechanism could be that cardiac
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35059troponin T release is the result of dislodgement of small localized
thrombi, causing micro-injury in small coronary vessels. Recently,
a number of studies were published, which focused on the
prognostic value of hs-cTnT. Most of these studies were performed
in the elderly or the general population [10–13]. Less is known
about the possible incremental value of hs-cTnT on top of existing
risk stratification tools in patients visiting the cardiology outpatient
department because of symptoms of chest discomfort suspected for
CAD.
In the present study, we investigated the prognostic value of hs-
cTnT in symptomatic patients with suspected CAD, and assessed
its additional value in combination with other risk stratification
tools in predicting cardiac events. As a comparison, we also studied
hsCRP and NT-proBNP.
Methods
Ethics statement
This study complies with the Declaration of Helsinki and all
patients gave written informed consent. The study was approved
by the Institutional Review Board and Ethics Committee at the
Maastricht University.
Study population
We studied 1,114 patients with symptoms of chest discomfort
who were referred from the cardiology outpatient department for
CCTA because of suspected CAD, according to the appropriate-
ness criteria for cardiac computed tomography [14]. All scans
were performed in our university medical center between 2007
and 2009. Part of this population was studied previously [8].
Included were patients with a recent history of chest discomfort
symptoms in the presence of additional cardiovascular risk factors
and/or inconclusive diagnostic test results, resulting in a
population with an intermediate pretest probability of CAD.
Excluded were eight patients with missing data regarding their
cardiovascular risk profile and eighteen patients with a history of
proven CAD, acute myocardial infarction (AMI), percutaneous
coronary intervention (PCI) or coronary artery bypass grafting
(CABG). The remaining 1,088 patients were subject of this study
(Figure 1). Patients who were referred from the emergency
department for CCTA because of acute chest pain, suspect for an
acute coronary syndrome (ACS), were not included in this study.
In general, patients with an allergy to iodinated contrast agent,
pregnant patients and patients with an impaired renal function
(defined as an estimated glomerular filtration rate ,45 mL/min/
1.73 m
2) were ineligible for CCTA.
Cardiovascular risk factors
Cardiovascular risk factors were prospectively gathered in order
to calculate the Framingham risk score (FRS). The FRS is used to
estimate the 10-year risk of suffering a myocardial infarction or
cardiovascular death, based on age, gender, diabetes mellitus,
smoking, systolic blood pressure, total cholesterol, and high-
density lipoprotein (HDL) [15]. Patients were classified as smokers
if they had smoked in the 12 weeks before CCTA. A positive
family history was defined as having a first-degree relative with a
history of myocardial infarction or sudden cardiac death before
the age of sixty.
Echocardiography acquisition
Echocardiography (Sonos 5500, Hewlett Packard, Palo Alto,
CA, USA) was performed in 612 patients, using Xcelera software
(Philips Healthcare, Best, the Netherlands). The left ventricular
ejection fraction (LVEF) was assessed using 2D echo images. To
assess the presence of left ventricular hypertrophy (LVH), we used
three parameters: interventricular septum end-diastolic wall
thickness (IVSEDWT), posterior wall end-diastolic wall thickness
(PWEDWT) and left ventricular mass (LVMASS). Measurement
of the IVSEDWT and PWEDWT were performed in the
parasternal long axis.
Coronary CT-angiography acquisition
CT-scans were performed in all patients using a 64-slice
multidetector-row CT-scanner (Brilliance 64, Philips Healthcare)
with a 6460.625-mm slice collimation, a gantry rotation time of
420 ms and a tube voltage of 80–120 kV, depending on the
patient’s height and weight. Patients received 50 mg metoprolol
tartrate orally, two hours before CCTA, to lower the heart rate
(HR). When the HR was .65 beats per minute (bpm), 5–20 mg
metoprolol tartrate (AstraZeneca, Zoetermeer, the Netherlands)
was administered intravenously. All patients received 0.8 mg
nitroglycerin spray (Pohl-Boskamp, Hohenlockstedt, Germany).
HR and ECG were continuously monitored.
A non-enhanced scan was performed to determine the CCS
using the Agatston method [16]. Subsequently, CCTA was
performed using 85–110 mL contrast agent (Xenetix 350,
Guerbet, Roissy CdG Cedex, France), which was injected in the
antecubital vein with a flow rate of 6.0 mL/s, directly followed by
40 mL saline (6.0 mL/s) using a dual-head power injector. In
patients with a stable HR,65 bpm, a prospective ECG-gated
‘step and shoot’ protocol was used (radiation dose 3.561.2 mSv).
In patients with a HR .65 bpm, a retrospective ECG-gated
‘helical’ protocol with dose modulation was used (radiation dose
11.863.6 mSv).
Coronary plaque assessment
All scans were independently analyzed by two cardiologists,
both with level III expertise in coronary CT-angiography and
blinded for patient details, using source images in Cardiac
Comprehensive Analysis software (Philips Healthcare). In case of
disagreement, consensus was reached by reviewing findings jointly.
Figure 1. Flowchart of the study design. * Early revascularizations
within 90 days after CCTA were censored at the time of PCI or CABG.
doi:10.1371/journal.pone.0035059.g001
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software (Philips Healthcare) with a threshold of 130 Hounsfield
units. The coronary tree was analyzed for the presence and
severity of CAD, according to the 16-segment classification of the
American Heart Association [17]. The extent of CAD was
classified as absent, mild (,50% luminal stenosis), moderate (50–
70% luminal stenosis) or severe ($70% luminal stenosis),
according to the guidelines of the Society of Cardiovascular
Computed Tomography [18].
Biomarker measurement
Samples were collected just before the scan, processed within
two hours, and stored at 280uC until analysis. Total cholesterol,
HDL and triglycerides concentrations were measured using the
Synchron LX20 (Beckman Coulter Inc., Brea, CA, USA). Low-
density lipoprotein (LDL) was calculated using the Friedewald
equation [19] except for subjects with triglycerides .400 mg/dL
and total cholesterol ,50 mg/dL, in which case LDL was
determined on the Cobas Mira Plus (Roche Diagnostics, Basel,
Switzerland). HsCRP was measured on the BN ProSpec using the
CardioPhase hsCRP assay (Siemens Diagnostics, Deerfield, IL,
USA). Hs-cTnT (high sensitivity fifth generation cTnT assay) and
NT-proBNP were measured on the Elecsys 2010 (Roche
Diagnostics).
Study endpoint and follow-up
The composite study endpoint was the occurrence of revascu-
larization (PCI/CABG) .90 days after CCTA, cardiac mortality
and ACS, including myocardial infarction and unstable angina
requiring hospitalization. ACS was defined as typical angina
pectoris, troponin T elevation (.0.01 mg/L) and ST-segment
elevation/depression of $1 mm, or at least two of these
characteristics together with invasive angiographic confirmation
of a culprit lesion [20]. So, this means that patients with only
troponin T elevation did not meet the criteria for an ACS. We
censored follow-up when revascularization was performed within
90 days and after occurrence of the study endpoint. Patients were
seen by their cardiologist on a regular basis, and all hospital visits,
both outpatient department visits as well as emergency room visits,
were recorded in the electronic patient records. Additionally, the
national mortality records were checked. None of the attending
clinicians had access to the results of the hs-cTnT, hsCRP and
NT-proBNP measurements.
Statistical analysis
To test for differences in baseline patient characteristics, we
used the Pearson x
2 test for discrete variables and the t-test for
continuous variables. Logistic regression and survival analysis were
used to study prediction of the composite endpoint of late
revascularization procedures (PCI/CABG), ACS, and cardiac
mortality. Confounding was considered for baseline characteristics
that differed significantly between the event group and non-event
group. For Kaplan-Meier analysis, categories of independent
variables were compared using the log-rank test. Cox proportional
hazard regression was validated for proportionality using log-
minus-log and for time dependency. It was used to evaluate the
additive value of the cardiac biomarkers, based on the Chi-square
change (22 log likelihood ratio) and whether biomarkers remained
significant predictors. Biomarker concentrations less than the limit
of detection were set equal to the limit of detection. The threshold
for statistical significance was P,0.05, two-sided unless stated
otherwise. All data were analyzed using SPSS Statistics 18.0 (SPSS
Inc., Chicago, IL, USA).
Results
The baseline characteristics of the 1,088 patients who met the
inclusion and exclusion criteria are presented in Table 1. Follow-
up information was available for all patients (mean follow-up time
2.260.8 years). As a result of CCTA, 50 patients underwent (early)
revascularization within 90 days (356PCI, 156CABG) and these
were censored at the time of revascularization. Final survival
analysis included a total of 42 patients who suffered a cardiac
event: 26 patients underwent (late) revascularization .90 days
after CCTA (206 PCI and 66 CABG), 15 patients suffered an
ACS (66AMI and 96unstable angina requiring hospitalization),
and one patient died due to heart failure. The overall cardiac
event rate was 4%.
Table 1 shows that patients who suffered a cardiac event
consisted of significantly more smokers, had higher systolic blood
pressure and FRS, higher hs-cTnT concentrations, lower LVEF,
higher CCS, and more severe lesions on CCTA.
Prognostic value of hs-cTnT
Logistic regression revealed that 1-unit increase in hs-cTnT
concentration resulted in a significant increase in cardiac risk (HR
1.04, 95% CI 1.01–1.06, P=0.004), in contrast to NT-proBNP
(HR 1.00, 95% CI 1.00–1.00, P=0.645) and hsCRP (HR 1.00,
95% CI 0.98–1.03, P=0.712). Comparable results were obtained
when biomarker concentrations were corrected for age and
gender.
Kaplan-Meier analysis shows that hs-cTnT and NT-proBNP
concentrations were both significant predictors for the occurrence
of cardiac events (P,0.001 and P=0.009, respectively), in contrast
to hsCRP (P=0.355). Moreover, Cox regression reveals that hs-
cTnT was the only significant biomarker predicting for cardiac
events, either when testing the biomarker concentrations as a
continuous variable (Table 2: Model 1, 4, and 7, respectively) or
when present in the highest quartile Q4 (Table 2: Model 2, 5, and
8, respectively).
Additional value of hs-cTnT on top of FRS
Clinical risk profiling using FRS predicted significantly for the
occurrence of cardiac events (Table 1, P,0.001). This was
confirmed using logistic and Cox regression for FRS as a
continuous variable or when categorized as follows: ,5% (low
risk), 5–20% (intermediate risk), .20% (high risk) (all P,0.05).
Kaplan-Meier analysis confirmed this relation, as shown in
Figure 2A (P=0.018). Noticeably, almost no cardiac events were
observed in patients with FRS,5%.
When regarding time to event using Cox regression, hs-cTnT
concentrations were predictive on top of FRS (Table 3, without
versus with hs-cTnT). This was true when hs-cTnT was added to
the individual parameters of the FRS (Model 1: HR hs-cTnT 1.02,
P=0.007 and Chi-square change 5.23, P=0.022) or marginally
significant when added to the complete FRS algorithm (Model 2:
HR hs-cTnT 1.02, P=0.018 and Chi-square change 3.58,
P=0.058). To further illustrate, we noticed a 3-fold increase in
cardiac risk in patients with hs-cTnT concentrations in Q4 as
compared to ,Q4, independent from high or low FRS (cut-off
20%) (Model 3: HR hs-cTnT 3.11, P=0.001 and Chi-square
change 10.56, P=0.001). In patients with FRS,20%, the cardiac
event rate increased from 2.1% to 5.9% when hs-cTnT
concentrations were in Q4 compared to ,Q4. In patients with
FRS.20%, the cardiac event rate increased from 3.6% to 10.6%,
respectively. This is also illustrated using Kaplan-Meier analysis in
Figure 2B (P=0.001). In contrast, no significant additional value
was found for NT-proBNP and hsCRP.
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Baseline characteristics All Participants No Event Cardiac Event * P value
(n=1,088) (n=1,046) (n=42)
Age, mean (SD), years 56 (11) 56 (11) 59 (11) 0.067
Male gender, % 53.8 53.6 57.1 0.655
Systolic BP, mean (SD), mmHg 142 (19) 141 (19) 149 (16) 0.010
Smoking, % 26.5 25.6 50.0 0.001
Diabetes mellitus, % 8.4 8.3 12.5 0.347
Positive family history, % 39.7 39.2 51.2 0.123
Framingham risk score, median (IQR) 16.7 (9.3–27.2) 16.4 (9.2–26.4) 25.1 (14.6–48.1) ,0.001
Total cholesterol, mean (SD), mg/dL 206.1 (46.3) 205.7 (46.2) 215.7 (47.1) 0.179
LDL-C, mean (SD), mg/dL 127.6 (41.4) 127.3 (41.5) 134.0 (40.5) 0.303
HDL-C, mean (SD), mg/dL 50.4 (29.9) 50.5 (30.3) 47.9 (16.0) 0.581
Triglycerides, mean (SD), mg/dL 153.2 (102.6) 152.6 (102.9) 166.5 (93.3) 0.391
hsCRP, median (IQR), mg/dL 0.14 (0.07–0.31) 0.14 (0.07–0.31) 0.16 (0.10–0.48) 0.079
hs-cTnT, 5th generation assay, median
(IQR), pg/mL
4.1 (,3.0–6.7) 4.0 (,3.0–6.6) 6.8 (,3.0–10.3) 0.015
NT-proBNP, median (IQR), pg/mL 75.5 (34.3–153.2) 74.2 (33.4–155.4) 92.3 (55.2–136.6) 0.218
LVEF, mean (SD), % { 60.3 (7.8) 60.4 (7.7) 57.2 (9.4) 0.048
IVSEDWT, mean (SD), mm { 8.9 (1.7) 8.9 (1.7) 9.5 (1.7) 0.103
PWEDWT, mean (SD), mm { 8.7 (1.1) 8.7 (1.1) 9.3 (1.4) 0.060
LVMASS, mean (SD), gram { 185 (55) 185 (54) 198 (72) 0.252
Calcium score, median (IQR) 7 (0–122) 6 (0–110) 252 (8–644) ,0.001
CCTA luminal stenosis, % ,0.001
No CAD 36.8 37.9 9.5
Mild CAD (,50%) 38.1 39.0 16.7
Moderate CAD (50–70%) 14.5 14.0 28.6
Severe CAD (.70%) 10.5 9.2 45.2
*Cardiac events: PCI.90 days, CABG.90 days, ACS, cardiac mortality.
{n=612 underwent echocardiography.
BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitive C-reactive protein; hs-cTnT, high-
sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; LVEF, left ventricular ejection fraction; IVSEDWT, interventricular septum end-
diastolic wall thickness; PWEDWT, posterior wall end-diastolic wall thickness; LVMASS, left ventricular mass; CCTA, coronary CT-angiography; CAD, coronary artery disease.
doi:10.1371/journal.pone.0035059.t001
Table 2. Cox regression analysis of cardiac biomarkers for the composite endpoint of cardiac events.
Model Cardiac biomarker Chi-square P value HR 95% CI P value
1 hs-cTnT 28.93 ,0.001 1.03 1.01–1.04 ,0.001
2 hs-cTnT in Q4 (.6.7 ng/L) * 17.30 ,0.001 3.55 1.88–6.70 ,0.001
3 hs-cTnT.URL (14 ng/L) *
,{ 1.08 0.299 1.85 0.57–6.02 0.307
4 NT-proBNP 0.84 0.359 1.00 1.00–1.00 0.380
5 NT-proBNP in Q4 (.18 pmol/L) * 0.72 0.396 0.70 0.31–1.60 0.399
6 NT-proBNP.URL (36 pmol/L) *
,{ 0.47 0.492 0.66 0.20–2.16 0.495
7 hsCRP 0.11 0.742 1.00 0.98–1.02 0.746
8 hsCRP in Q4 (.3.1 mg/L) * 0.86 0.355 1.38 0.70–2.73 0.357
9h s C R P .URL (3 mg/L) *
,{ 0.61 0.436 1.31 0.66–2.60 0.437
*Dichotomous variable (yes or no); Q4, fourth quartile.
{URL=upper reference limit (used for diagnosis).
hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-brain-type natriuretic peptide; hsCRP, high-sensitive C-reactive protein.
doi:10.1371/journal.pone.0035059.t002
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cardiac event group as compared to the non-event group
(P=0.048). Cox regression confirmed LVEF as a significant
predictor (HR 0.96, 95% CI 0.93–1.00, P=0.049). Nevertheless,
the predictive value of hs-cTnT remained significant when
corrected for LVEF (HR hs-cTnT 1.02, 95% CI 1.01–1.04,
Figure 2. Kaplan-Meier analyses illustrating improved classification by including hs-cTnT to current risk stratification tools. Figures
on the left shows Kaplan-Meier curves for FRS (A), CCS (C) and CCTA assessment (E). Figures on the right shows Kaplan-Meier curves when hs-cTnT
was added to FRS (B), CCS (D) and CCTA assessment (F). Q4=fourth quartile of hs-cTnT concentrations.
doi:10.1371/journal.pone.0035059.g002
High-Sensitivity Troponin T in Risk Stratification
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35059P=0.002 and HR LVEF 0.97, 95% CI 0.93–1.01, P=0.124).
When LVEF was added to risk profiling as presented in Table S1
(supplemental data), smoking (Model without hs-cTnT) or
smoking and hs-cTnT (Model with hs-cTnT) remained the only
significant predictors.
Additional value of hs-cTnT on top of CCS and CCTA
Kaplan-Meier analysis shows an apparent gradient of adverse
survival for more severe CAD (Figure 2C and 2E). Furthermore,
hs-cTnT concentrations (median, IQR) were significantly higher
in mild (4.2 pg/mL, ,3.0–7.3), moderate (4.7 pg/mL, ,3.0–7.3),
and severe CAD (6.5 pg/mL, 3.6–9.4) as compared to patients
without CAD (3.3 pg/mL, ,3.0–5.3), all P,0.001. A similar
trend was found for CCS (P,0.001). These data show that
increasing concentrations of hs-cTnT were associated with the
severity of CAD, which is in line with our previous results in part
of this population [8].
Cox regression in Table 4 shows the additional value of hs-
cTnT on top of CAD assessment with CCS and CCTA. One unit
increase in hs-cTnT resulted in a minor increase in cardiac risk
(Model 1 CCS: HR hs-cTnT 1.02, P=0.006 and Chi-square
change 4.23, P=0.040; Model 3 CCTA: HR hs-cTnT 1.01,
P=0.028 and Chi-square change 3.04, P=0.081). To illustrate, a
2- to 3-fold increase in cardiac risk was noticed in patients with hs-
cTnT concentrations in Q4, independent from high or low CCS
(cut-off Agatston score 400) or luminal stenosis on CCTA (cut-off
70%) (Model 2 CCS: HR hs-cTnT 2.73, P=0.007 and Chi-square
change 7.20, P=0.007; Model 4 CCTA: HR hs-cTnT 2.47,
P=0.007 and Chi-square change 7.24, P=0.007. In patients with
high CCS (Agatston score .400, n=85), the cardiac event rates
increased from 4.3% to 24% when hs-cTnT concentrations were
in Q4 as compared to ,Q4. In patients with a CCTA lesion of
.70% luminal stenosis (n=103), the cardiac event rates were
8.8% and 28% when hs-cTnT concentrations were in ,Q4 and
Q4, respectively. This is also illustrated using Kaplan-Meier
analysis in Figure 2D and 2F for CCS and CCTA assessment,
respectively (both P=0.001). Again, no significant additional value
was found for NT-proBNP and hsCRP.
Discussion
Our study shows that in patients with symptoms of chest
discomfort suspected for CAD, hs-cTnT was a significant
predictor for the composite endpoint of late revascularizations,
ACS and cardiac mortality. Over three times as much cardiac
events were found in patients with hs-cTnT concentrations in the
fourth quartile (cut-off 6.7 ng/L, HR 3.55, P,0.001) as compared
to patients with hs-cTnT concentrations in the lowest three
quartiles. Moreover, survival analysis showed that hs-cTnT
significantly contributed to the identification of a subgroup of
patients with higher risk for cardiac events. When using traditional
risk factors, smoking (HR 3.34, P=0.001), hs-cTnT (HR 1.02,
P=0.007), and systolic blood pressure (HR 1.02, P=0.030)
remained the only significant predictors. Hs-cTnT remained
significantly predictive independent from FRS (HR 1.02–3.11,
dependent whether variables were continuous or categorized). In
addition, hs-cTnT improved classification on top of the extent of
CAD as assessed with CCS and CCTA. To illustrate, a 2- to 3-fold
increase in cardiac risk was noticed in patients with hs-cTnT
concentrations in the highest quartile, independent from high or
low CCS (cut-off Agatston score 400) or luminal stenosis on
CCTA (cut-off 70%) (HR 2.73 and 2.47, both P=0.007).
In a previous study, Reichlin et al showed that the positive
predictive value of hs-cTnT in diagnosing acute myocardial
infarction was only 19% (cut-off 2 pg/mL, limit of detection) or
50% (cut-off 14 pg/mL, 99
th percentile of healthy reference
population), while the negative predictive value was nearly perfect
(99–100%, dependent on cut-off) [5]. This indicates that it is of
great importance to exclude false positives before widespread
introduction of hs-cTn as a risk factor. On the other hand, the
present study as well as other studies has shown the adverse
outcome of elevated hs-cTn on cardiovascular events [10–
12,21,22]. The reference change value for hs-cTnT concentra-
tions, that is based on biological variations in healthy individuals
and analytical variations, was 58% and around 95% for the short-
term (4 hours) and long-term (8 weeks), respectively [23]. There
are no results reported on optimal delta cut-offs considering a
longer follow-up period of years apart from the study of deFilippi
et al, who recently showed that for an increase in hs-cTnT
concentrations .50% over two to three years, the risk for heart
failure and cardiovascular death were 1.7 and 1.8-fold, respec-
tively [11].
Question remains what the underlying pathophysiological
mechanisms of elevated hs-cTnT concentrations in these patients
are. Korosoglou and colleagues concluded that the presence of
non-calcified coronary plaques may result in continuous leakage of
troponins, possibly due to repetitive micro-embolization of
atherosclerotic debris [9]. In our study, we observed a stepwise
increase in hs-cTnT concentrations with increasing atherosclerotic
plaque burden which supports this explanation. Alternative
explanations for troponin leakage which have been supposed are
demand ischemia, myocardial ischemia (for example due to
coronary vasospasm), direct myocardial damage, chronic renal
insufficiency, or myocardial strain because of volume or pressure
overload [24]. Other possible causes of elevated hs-cTnT
concentrations could be chest trauma, strenuous exercise,
pericarditis, myocarditis and cardiac amyloidosis. However, in
the present study we could exclude chest trauma and strenuous
exercise as causes. Furthermore, ECG findings, CCTA and
Table 3. Cox regression analysis of Framingham risk profiling
for the composite endpoint of cardiac events.
Models Without hs-cTnT With hs-cTnT
HR 95% CI P value HR 95% CI P value
Model 1
Age 1.03 1.00–1.07 0.074 1.02 0.98–1.06 0.332
Male gender * 1.26 0.61–2.63 0.531 1.12 0.53–2.36 0.770
Total cholesterol 1.11 0.84–1.47 0.468 1.16 0.87–1.54 0.308
HDL cholesterol 0.92 0.45–1.88 0.812 0.92 0.44–1.88 0.811
Systolic blood pressure 1.02 1.00–1.03 0.071 1.02 1.00–1.04 0.030
Smoking * 3.73 1.83–7.60 ,0.001 3.34 1.62–6.92 0.001
Diabetes mellitus * 1.32 0.44–3.94 0.618 0.95 0.27–3.35 0.939
hs-cTnT - - - 1.02 1.01–1.04 0.007
Model 2
Framingham 1.03 1.02–1.04 ,0.001 1.03 1.01–1.04 ,0.001
hs-cTnT - - - 1.02 1.00–1.03 0.018
Model 3
Framingham .20% * 2.33 1.19–4.55 0.013 1.79 0.89–3.57 0.101
hs-cTnT in Q4 * - - - 3.11 1.58–6.11 0.001
*Dichotomous variable (yes or no). HDL, high-density lipoprotein; hs-cTnT, high-
sensitivity cardiac troponin T; Q4, fourth quartile.
doi:10.1371/journal.pone.0035059.t003
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tive diagnoses like pericarditis, myocarditis or amyloidosis. Since
concentrations of NT-proBNP were not increased in our patients,
we felt we could exclude digestive heart failure as cause of the
increased hs-cTnT concentrations.
Recently, two papers were published which feed the thought
that the identification of patients at risk for a cardiovascular event
may soon become easier and more accurate using hs-cTnT
[10,11]. DeFilippi et al performed serial measures of hs-cTnT in
community-dwelling older adults [11]. They found a significant
association between baseline hs-cTnT concentrations, changes in
hs-cTnT concentrations and the development of heart failure and
cardiovascular death. De Lemos et al found an association
between increased hs-cTnT and structural heart disease, especially
left ventricular hypertrophy, and subsequent risk for all-cause
mortality [10]. However, the study by deFilippi was focusing on
elderly with a mean age above 70 years, while in the study of de
Lemos the vast majority of the population (77%) consisted of
patients with FRS ,10%. These characteristics are not typical for
the patients presenting at the cardiology outpatient department.
Therefore, it is not clear from those studies to what extent hs-
cTnT would be of incremental value in patients presenting with
symptoms of chest discomfort at the cardiology outpatient
department. Moreover, the published studies focused on left
ventricular hypertrophy and heart failure, respectively. It is not
inconceivable that the main cause of the elevated hs-cTnT is the
presence of atherosclerosis, because it is known that the majority of
patients with heart failure have underlying coronary atheroscle-
rotic disease [25]. Moreover, hypertension is an important risk
factor for atherosclerosis and also the major determinant of left
ventricular hypertrophy. In this study, we show that although the
predictive value of LVEF for events was significant, this did not
seem to confound our results. In previous work, we demonstrated
that even mild CAD is associated with increased concentrations of
hs-cTnT and we suggested that hs-cTnT may become a potential
serum biomarker to improve the identification of patients at risk
for developing cardiovascular events [8]. There is increasing
evidence that ACS may be predominantly caused by such mild
stenoses [26]. On the other hand, it is known that the extent of
CAD provides important prognostic information in both asymp-
tomatic and symptomatic patients. Both high CCS and $50%
luminal stenosis on CCTA deprive prognosis significantly [27]. In
this study we show that measuring hs-cTnT provides additional
value on these already strong prognostic parameters. In our
opinion, these findings strengthen the hypothesis that hs-cTnT is a
prognostic clinical biomarker. In addition, we provide new insights
into the use of hs-cTnT, which can help the physician to better
identify the patient at risk of a cardiovascular event.
This study has several limitations that merit comment. First, the
follow-up period is relatively short and therefore we found
relatively few events. However, the event rate which we found is
comparable to other previously published large CCTA-trials.
Second, clinicians were not blinded for CCTA findings.
Therefore, early revascularizations (within 90 days) were censored
for survival analysis. However, the knowledge of the CCTA
findings could still bias the clinician’s behaviour after the 90 day
time period. It would be interesting to blind clinicians for CCTA
results, but since CCTA is part of the diagnostic work-up in our
university medical center, this would be unethical. On the other
hand, none of the clinicians had access to the results of the hs-
cTnT, hsCRP and NT-proBNP measurements. Third, all patients
were of Western European descent. It remains uncertain whether
our results can be generalized to other populations. Fourth, we
performed a single hs-cTnT measurement and it remains unclear
in which manner hs-cTnT varies in time. Fifth, despite the fact
that invasive coronary angiography is still the golden standard for
coronary artery stenosis, we are convinced that the use of CCTA
gives an adequate reflection of the extent and severity of plaque
burden in our study population.
Table 4. Cox regression analysis of coronary plaque assessment for the composite endpoint of cardiac events.
Models Without hs-cTnT With hs-cTnT
HR 95% CI P value HR 95% CI P value
CCS Model 1
CCS 1.00 1.00–1.00 ,0.001 1.00 1.00–1.00 ,0.001
hs-cTnT - - - 1.02 1.01–1.04 0.006
CCS Model 2
CCS.400 * 5.68 2.72–11.86 ,0.001 4.53 2.13–9.64 ,0.001
hs-cTnT in Q4 * - - - 2.73 1.32–5.62 0.007
CCTA Model 3
Luminal stenosis on CCTA: ,0.001 ,0.001
No CAD=reference 1.00 1.00
,50% 1.47 0.42–5.22 0.549 1.44 0.41–5.11 0.571
50–70% 7.25 2.27–23.11 0.001 7.09 2.22–22.62 0.001
.70% 23.98 8.10–70.96 ,0.001 21.76 7.27–65.10 ,0.001
hs-cTnT - - - 1.01 1.00–1.03 0.028
CCTA Model 4
luminal stenosis on CCTA.70% * 11.33 5.98–21.47 ,0.001 9.23 4.79–17.82 ,0.001
hs-cTnT in Q4 * - - - 2.47 1.29–4.77 0.007
*Dichotomous variable (yes or no). CCS, coronary calcium score; CCTA, coronary CT-angiography; hs-cTnT, high-sensitivity cardiac troponin T; CAD, coronary artery
disease; Q4, fourth quartile.
doi:10.1371/journal.pone.0035059.t004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35059In conclusion, hs-cTnT is a useful prognostic biomarker in
patients with symptoms of chest discomfort suspected for CAD.
Hs-cTnT is associated with the extent of CAD, assessed by CCS
and CCTA, and is a significant predictor for the occurrence of a
future cardiac event (late revascularization, ACS, and cardiac
mortality). Even better performance was obtained when hs-cTnT
concentrations were combined with Framingham risk profiling.
Finally, hs-cTnT also provided additional value to the assessment
of CAD by coronary computed tomography.
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